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Abstract: Asthma is a chronic inflammatory disorder of the airways that requires long-term 
treatment, the goal of which is to control clinical symptoms for extended periods with the 
least possible amount of drugs. International guidelines recommend the addition of an inhaled 
long-acting beta2-agonist (LABA) to a low- to medium-dose inhaled corticosteroid (ICS) 
when low doses of ICS fail to control asthma symptoms. The fixed combined administration 
of ICS/LABA improves patient compliance, reducing the risk of therapy discontinuation. 
The relative deposition pattern of the inhaled drug to the target site is the result of a complex 
interaction between the device used, the aerosol formulation and the patient’s adherence to 
therapy. Different inhalation devices have been introduced in clinical practice over time. The 
new hydrofluoroalkane (HFA) solution aerosols allow for the particle size to be modified, 
thus leading to deeper penetration of the medication into the lung. The Modulite® technology 
allows for the manipulation of inhaled HFA-based solution formulations, such as the fixed 
beclomethasone/formoterol combination, resulting in a uniform treatment of inflammation and 
bronchoconstriction. The success of any anti-asthmatic treatment depends on the choice of the 
correct device and the adherence to therapy.
Keywords: asthma, therapy, inhalers, compliance
Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by a vari-
able degree of airway obstruction, which can reverse spontaneously or after treat-
ment, and an underlying condition of exaggerated airway narrowing in response to 
external stimuli. The chronic features of the disease imply a long-term treatment to 
attain optimal control of the respiratory symptoms. Indeed, the goal of treatment is 
to achieve and maintain control of clinical symptoms for extended periods with the 
least possible amount of drugs.
Control of the disease is optimal when the patient presents with no diurnal or 
night-time symptoms, no limitation of daily activities including exercise, minimum 
use of beta2-agonists, and no need for hospitalization. According to epidemiological 
observations, a variable proportion of the asthmatic population does not control the 
disease because of factors that include inadequate drug treatment, and lack of adher-
ence to the recommended drug therapy or to the device. In addition, physicians and 
patients tend to underestimate the intensity and frequency of symptoms, and the need 
to monitor the disease. The occurrence of inadequate physician–patient communication 
also contributes to the lack of optimal control. As already cited, the lack of adherence to 
therapy strongly impacts on the control of the disease. Cramer et al1 demonstrated that 
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the frequency of drug administration influences adherence to 
treatment, decreasing from 87% with one administration per 
day to 39% when four administrations per day are requested. 
Long-term treatment as a factor affecting adherence to 
treatment was shown in a 1-year study conducted in adults 
and children:2 at the end of the study, only 15% of patients 
was still receiving inhaled treatment regularly. Above all, it 
appears pertinent to state that drugs don’t work in patients 
who don’t take them!
Several epidemiological studies have been conducted 
in an effort to determine whether asthma control is attain-
able and in what proportion of patients. The AIRE (Asthma 
Insights and Reality in Europe) study,3 conducted on a sam-
ple of 2803 patients to examine the management of asthma 
in Europe, showed that despite the existence of highly effec-
tive treatments, frequent daytime and nocturnal symptoms 
and limitations of daily activities are reported by patients, 
including a high frequency of requests for unscheduled doc-
tor visits, emergency department visits, and hospitalization 
for serious exacerbations. The ISAYA study4 confirmed 
that the inappropriate use of drugs is mainly responsible 
for failure to control asthma. This study found that 47% 
of persistent asthmatics that participated in the survey in 
Italy were using combination therapy that was inadequate 
for the severity level (too low a dosage of corticosteroids 
and/or inappropriate treatment), and that 64% of asthmatics 
were on an irregular treatment that should have been taken 
daily. The study confirmed that for each degree of severity, 
regularity of treatment was associated with better control 
of symptoms.
In evaluating whether optimal asthma control is attainable 
with current therapeutic options, the GOAL study5 showed 
that asthma control can be reached in a high percentage of 
patients, and this occurs more frequently when a regimen 
is implemented based on the degree of severity. The study 
provided evidence that the salmeterol/fluticasone combina-
tion is more effective than treatment with fluticasone alone 
in achieving good asthma control. Of particular importance 
is the finding that the salmeterol/fluticasone combination 
was able to control symptoms more quickly and at a lower 
dose of corticosteroid. The observed improvements in several 
clinical and functional parameters were clinically relevant 
and sustained over time, stressing the importance of regular 
and prolonged treatment.
Inhaled therapy in asthma
The cornerstone of the daily control of asthma is inhaled 
therapy. In this respect, direct delivery of the aerosolized 
drug in the lower airways is advocated to treat inflammation 
and to relieve obstruction. In comparison with oral therapy, 
the inhaled pathway allows the minimization of effective 
doses and consequently minimization of adverse systemic 
effects, particularly important for long-term treatments often 
necessary in asthma. On the other hand, several variables 
affect the inhaled pathway, mostly related to the drug for-
mulation and delivery device. Pharmacological treatment of 
asthma requires a stepwise approach based on the severity 
of the disease, which can be adapted continuously accord-
ing to the clinical control of the disease. The ultimate goal 
of treatment is to achieve and maintain control of clinical 
symptoms for extended periods with the least possible 
amount of drugs.
Inhaled glucocorticosteroids (ICS) represent first-line 
treatment for the management of asthma, in that they are the 
most effective anti-inflammatory medications for the treat-
ment of persistent symptoms (Table 1). Most studies have 
demonstrated their efficacy in controlling airway inflamma-
tion,6 reducing symptoms, improving quality of life and lung 
function, decreasing airway hyper-responsiveness,7 reduc-
ing frequency and severity of exacerbations,8 and reducing 
asthma mortality.9 International guidelines recommend the 
addition of an inhaled long-acting beta2-agonist (LABA) to 
a low- to medium-dose ICS when low doses of ICS fail to 
control asthma symptoms.10 Randomized clinical trials with 
LABA in combination with corticosteroids have demon-
strated that the addition of LABA to ICS is more beneficial 
in terms of asthma control and pulmonary function than 
increasing the dose of ICS alone.11–14 When administered 
as fixed combination, the administration of ICS/LABA has 
been demonstrated to improve patient compliance, thus 
Table 1 effects of glucocorticoids on the pathogenic mechanisms 
of airway inflammation
Inhibit the production of proinflammatory cytokines
Reduce the number of mast cells, eosinophils, and other inflammatory 
cells of the airways
increase the beta2-adrenergic receptor responsiveness of the airways 
to sympathomimetic agents
Modulate the synthesis of ige in allergic-atopic subjects
interfere with the biosynthesis of eicosanoids
reduce nitric oxide production
Inhibit neurogenic inflammation
Prevent the activation and migration of inflammatory cells
reduce vasodilation of the microcirculation and thus the edema 
by plasma exudation
reduce the production of mucus
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reducing the risk of therapy discontinuation,15 compared to 
the administration of these components separately. There is 
evidence suggesting that LABA and ICS mutually potentiate 
their effects when given in combination.16
The aim of inhaled therapy is to allow the medication 
to reach the target site. This can be attained by ensuring the 
penetration of the aerosolized particles into the lower respira-
tory tract, and the deposition of the drug along the respiratory 
tract. Obviously, the deposition of the drug should translate 
into functional and clinical benefits. Taken together, these 
conditions also require the right choice of device.17 The rela-
tive deposition pattern of the inhaled drug is the result of a 
complex interaction between the aerosol formulation and 
the device used. A body of histological and functional evi-
dence has accumulated to confirm that the distal airways are 
the predominant site of airway inflammation in asthma;18–21 
therefore, the distal airways represent the main target of 
treatment (Figure 1), and the distribution of the drug along 
the bronchial tree should translate into higher efficacy of the 
inhaled therapy and reduced rate of adverse events. Most 
importantly, similar clinical benefit can be attained with a 
lower dose of the drug.22
The devices differ in terms of technical design (required 
inspiratory flow rate, actuation), composition (characteris-
tics of the propellant, carrier substances), dose per inhala-
tion, and costs. In addition, producers have made major 
efforts to make devices more user-friendly. The pressurized 
metered dose inhaler (pMDI) is the most widely used 
device.23 The major issue with the use of pMDIs is that the 
aerosol is fast-moving, which increases the risk of drug 
deposition in the pharynx, and therefore occurrence of 
local side-effects with limited clinical efficacy. The drug 
contained in the MDI canister is formulated as a suspension 
or solution, formulations which have different properties 
in terms of particle size, plume velocity and duration, as 
well as user friendliness, which affect drug delivery to the 
appropriate site. In the suspension formulation, the active 
drug is insoluble in the propellant and remains as solid 
powder; therefore, suspension formulations need to be 
shaken before inhalation to allow uniform distribution of 
solid powder particles of the drug. It has been demonstrated 
that a significant proportion of patients do not shake the 
device properly or present with coordination problems,24 
resulting in variable amounts of drug emitted in each 
aerosol puff. The occurrence of mistakes associated with 
the inhalation procedures can be reduced by regular train-
ing and follow-up. Other devices include breath-actuated 
pMDIs (BA-pMDI), such as Autohaler® and Easi-Breathe®, 
which incorporate a mechanism activated during inhalation 
that triggers the metered-dose inhaler. Dry powder inhal-
ers (DPIs) do not need coordination, as the drug is not 
driven by the propellant but is delivered by the inhalation 
effort. However, the actuation of the device needs high 
inspiratory flow to assure optimal drug delivery,25 which 
is crucial in the elderly. Indeed, Janssens and colleagues26 
recently demonstrated that, in elderly patients, the ability 
to generate sufficient inspiratory flow across a dry powder 
inhaler is compromised, irrespective of the presence of 
chronic obstructive pulmonary disease (COPD). Three 
types of DPIs are available with different handling instruc-
tions: single dose (Handihaler®, Aerolizer®), multiple doses 
(Diskus®) and reservoir (Turbohaler®). An official document 
on device selection and outcomes of aerosol therapy based 
on current literature reported that, when selecting a device 
for patients with asthma and COPD, the following should 
be considered: device/drug availability, patient age and the 
ability to use the selected device correctly, device use with 
multiple medications, and physician and patient prefer-
ence.27 Evidence-based guidelines for the device selection 
conclude that no difference between devices in any efficacy 
outcome has been recorded, provided that patients use the 
correct technique for inhalation. Therefore, the selection 
criteria should be related mainly to patient age, preference 
and ability to use the selected device correctly. Table 2 






Figure 1 Schematic of the bronchial tree with emphasis on the peripheral district, 
which is the main target of anti-asthmatic treatment.
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The Modulite® technology and the 
beclomethasone dipropionate/
formoterol combination
Since the 1987 Montreal Protocol that abolished chlorofluoro-
carbon (CFC) use in inhalers investigated, a hydrofluoroalkane 
propellant (HFA-134a) was developed as a nonozone-depleting 
CFC-free alternative for use in pMDI. The limits of the pMDI 
(difficulty to coordinate, low lung deposition, high oral 
deposition, need of a spacer) are not present in HFA inhalers, 
which are largely accepted by patients.28 Studies comparing 
beclometasone HFA with CFC inhalers showed no difference 
in terms of adverse events (oral thrush and hoarse voice).28 
The new HFA solution aerosols allow for the particle size 
to be modified, thus leading to deeper penetration of the 
medication into the lung.29 Recently, a new technology of 
the HFA solution pMDI has been developed:30 the Modulite® 
(Chiesi Ltd) platform technology allows for the manipulation 
of inhaled HFA-based solution formulations. This technol-
ogy offers the advantage of matching the CFC-based pMDIs 
with the HFA-MDIs on a 1:1 nominal dose ratio basis, thus 
favoring the transition to CFC-free formulations. Switching 
from CFC-MDI to HFA-MDI has been achieved successfully 
for corticosteroids31 and bronchodilators.32 Recently, the 
HFA-propelled extra-fine fixed combination formulation of 
beclometasone dipropionate/formoterol (BDP/F) 100/6 µg 
(Foster®) delivered via pMDI has been developed with the 
Modulite® technology. The BDP/F HFA pMDI combination 
is an extra-fine formulation, in which BDP dose is 2.5-fold 
lower than the conventional BDP CFC product (100 µg of 
BDP per actuation instead of 250 µg of nonextra-fine BDP). 
Furthermore, because of the small particle size of BDP/F, the 
two active drugs are delivered to both central and peripheral 
airways, resulting in a uniform treatment of inflammation and 
bronchoconstriction. The reduction in BDP dose lowers the 
amount of drug deposited in the upper airway, potentially 
improving the efficacy/safety ratio. Therefore, the optimized 
drug deposition that results from reduced particle size may 
lead to improved clinical benefit, as shown by Huchon et al.33 
The slower velocity and the longer duration of the plume 
reduce the throat deposition and improve the lung deposi-
tion of the drug.
Clinical efficacy and safety of 
beclomethasone/formoterol 
combination
A body of literature has demonstrated the efficacy and safety 
of both beclomethasone and formoterol separately and as 
fixed combination treatment, as reviewed by Nicolini et al,34 
and by Fabbri et al.35 The efficacy of the BDP/F fixed com-
bination was evaluated in a 3-month randomized controlled 
trial conducted in patients with moderate asthma who were 
still symptomatic despite receiving low-dose ICS.36 BDP/F 
given as one inhalation twice daily improved lung function 
by more than a double equipotent dosage of BDP nonextra-
fine. In patients with severe asthma,36 BDP/F given as two 
inhalations twice daily for 6 months showed improvement 
in peak expiratory flow and forced expiratory volume in 
1 second comparable to that of an equipotent nonextra-fine 
regimen of BDP and formoterol administered via separate 
inhalers, and was more effective than 1000 µg/day BDP 
nonextra-fine. Importantly, the BDP/F fixed combination 
was superior to both BDP plus formoterol in separate inhal-
ers and BDP monotherapy in terms of clinical measures of 
asthma control, suggesting that patients receiving extra-fine 
Table 2 Description of the main properties of different devices
Type Advantages Limitations




Used for different compounds
Need for coordination
Not suitable for children
High deposition in the pharynx
Dry powder inhaler (DPi) Portable
Actuation by inhalation
Less need for coordination
Used for different compounds
Need for high inspiratory flow
Not suitable for children
Not acceptable in emergencies
Negative effect of humidity on the drug
variable deposition in the pharynx
Nebulizer No need for coordination
No need for maximal inspiratory 
maneuvers
Suitable for all ages
Accepted in emergency situations
Allows for oxygen supplementation
Difficult to carry
Long inhalation sessions
Hygiene and maintenance issues
Possible degradation of the active drug 
(ultrasound)
variation in the amount of inhaled drug  
cost
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BDP/F may experience additional benefits to functional 
improvements.
Two studies with similar results37,38 were conducted to 
assess the efficacy and tolerability of BDP/F vs budesonide/
formoterol (BUD/F) and fluticasone propionate/salmeterol 
(FP/S), respectively. In the first study,38 patients who were 
taking BDP/F as two inhalations twice daily showed simi-
lar improvement in lung function, asthma symptoms and 
percentage of days without the use of rescue medication 
to that obtained with an equipotent regimen of BUD/F 
200/6 µg administered as two puffs twice daily. Interest-
ingly, BDP/F demonstrated similar onset of action to that of 
BUD/F. In the second study,37 BDP/F was compared with 
fluticasone propionate/salmeterol (FP/S) pMDI 125/25 µg, 
both administered as two puffs twice daily, and lung 
function improved similarly in both arms. In this study, 
the BDP/F group had a faster onset of bronchodilation as 
opposed to the FP/S group. This is of great importance, 
based on the fact that patients ask for immediate relief of 
symptoms, and this can drastically improve adherence to 
treatment and, consequently, asthma control. Of note, a 
greater improvement in forced vital capacity was shown in 
the BDP/F group, suggesting a greater effect on peripheral 
airways.
Patient perspectives and outcomes
Asthmatic patients are worried about three different aspects 
of the disease: asthmatic exacerbations, management of 
symptoms, and management of the disease during an 
exacerbation-free period. Even if asthmatic exacerbations 
could be the most important event in a patient’s life, the impact 
of asthma on everyday life could be an important factor also 
when asthma is asymptomatic. For the patient, the way of 
approaching emerging health-related problems depends on the 
severity of the clinical manifestations as well as on the strate-
gies that are used to solve them (coping strategies) and on pre-
vious experiences. Different studies have clearly confirmed a 
weak correlation between the magnitude of airway obstruction 
and the severity of asthmatic symptoms.39
It is therefore important to understand needs and expecta-
tions of asthmatic patients in order to obtain optimal disease 
management. Several surveys40,41 note that these patients 
have little information about their asthma and they live with 
diurnal and nocturnal symptoms. Moreover, these studies 
emphasize that patients are not completely satisfied with 
physician behavior. Moreover, patients often do not trust 
pharmacological treatment, and they are not convinced that 
therapy can completely control asthmatic symptoms.
Nowadays, effective diagnostic and therapeutic tools 
are widely available. In chronic diseases such as asthma, 
diagnosis and therapy are not sufficient to obtain the improve-
ment of health status. In fact, adherence to therapy, although 
often underestimated, is necessary to obtain optimal control 
of asthma; proper management of therapy is probably more 
useful then expensive investments to improve current thera-
pies. Nonadherence may involve up to 20% of patients who 
need treatment for a short period (10 days) because of an 
acute disease, up to 50% of patients affected by a chronic 
symptomatic disease, and up to 70% of those affected by 
a chronic asymptomatic disease. Coping strategies, which 
represent the way patients face the disease, determine 
individual differences in the psychological reactions towards 
asthma,42–45 which in turn influence the adherence to treat-
ment and quality of life.
Nonadherence can occur in only one phase of the treatment 
(eg, a patient takes drugs regularly but does not change their 
life-style, for example, they do not quit smoking); or it can 
occur in different phases of treatment (eg, some patients are 
more adherent to therapy during weekends than weekdays). 
Moreover, patients may spontaneously stop therapy to verify 
their recovery and efficacy of treatment. Nonadherence has 
some consequences for patients and their relatives, for the 
health system and for society. The consequences of nonad-
herence are shown in Table 3.
Several different factors reduce 
adherence to therapy
1. Factors related to treatment:46,47 complex medical 
treatment that requires the use of different drugs; the 
complexity of dosage and the different devices used for 
inhalation therapy; the side effects of medications.
2. Factors related to the patient: age; low perception of 
the disease; personal ideas about treatment; cognitive 
or physical impairments; psychological or psychiatric 
disorders; absence of family or social support; financial 
difficulties; the refusal to accept the disease.
3. Factors related to the health system organization: difficult 
admission to medical facilities; health welfare discontinu-
ation; high costs for patients.
4. Factors related to the relationship between physicians and 
patients:48 ineffective communication; inadequate patient 
or doctor behavior; inability to understand the patient 
perspectives on disease and treatment.
Different strategies can improve adherence to therapy.49 
These can be summarized as follows: improve patient–
physician communication, simplify the therapeutic plan 
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(if possible reduce the number of daily doses, using the 
simplest and most effective inhalator devices), and reduce 
the waiting lists. As stated by Juniper,50 both the clinician 
and the patient decide on the patient’s management plan, 
by negotiating a plan that the patient is willing to follow. 
A contractual agreement between patient and clinician may 
improve both clinical asthma control and patient health-
related quality of life.
Conclusions
Treatment of asthma aims at achieving and maintaining con-
trol of symptoms by using inhaled LABA and ICS. The fixed 
combined administration of ICS/LABA improves patient 
compliance, thus reducing the risk of therapy discontinu-
ation. The optimal control of asthma depends on the drug 
selected, the device used, and the elimination of factors that 
reduce patient adherence to therapy. Inhalers differs in their 
delivery technique, their efficiency, and their ease of use. 
The new aerosol technologies allow for the particle size to 
be modified, thus leading to deeper penetration of the medi-
cation into the lung. How a patient approaches the different 
components of the disease depends on the strategies they 
use to cope with them, which is why international asthma 
guidelines stress that before making changes to a patient’s 
therapy their compliance and inhaler technique should be 
checked. Adherence to treatment can be considered as the 
final result of interactions among the patient, the disease, the 
treatment, and the health system organization.
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